R Colodner1, I Kometiani, B Chazan, R Raz. 1. Clinical Microbiology Laboratory, Ha'Emek Medical Center, 18101, Afula, Israel. colodner_ra@clalit.org.il
Abstract
BACKGROUND: Resistance to fluoroquinolone drugs is emerging among E. coli causing community acquired urinary tract infections (COMA-UTI). OBJECTIVES: To evaluate demographic and clinical risk factors associated with COMA-UTI due to quinolone-resistant E. coli (QREc). METHODS: In this case-control study, clinical and demographic data from 300 COMA-UTI due to E. coli (including 150 QREc) were analyzed. RESULTS: By univariate analysis QREc was associated to males, older patients, nursing home residents, functionally dependent, dementia, diabetes, cardiovascular diseases, immunosupression, nephrolithiasis, recurrent UTI, invasive procedures, hospitalization, and antibiotic use within previous 6 months. By multivariate analysis, use of ciprofloxacin (OR 20.6 [CI 2.3-179.2], p=0.006) or ofloxacin (OR 7.5 [CI 2.9-19.4], p<0.0001), previous invasive procedure (OR 6.6 [CI 3.0-14.7], p<0.0001), recurrent UTI (OR 4.7 [CI 2.3-9.3], p<0.0001), and previous hospitalization (OR 2.9 [CI 1.4-6], p=0.003) were identified as independent risk factors for COMA-UTI due to QREc. CONCLUSION: In patients with one or more of the risk factors identified here, the empiric use of quinolones should be reconsidered.
BACKGROUND: Resistance to fluoroquinolone drugs is emerging among E. coli causing community acquired urinary tract infections (COMA-UTI). OBJECTIVES: To evaluate demographic and clinical risk factors associated with COMA-UTI due to quinolone-resistant E. coli (QREc). METHODS: In this case-control study, clinical and demographic data from 300 COMA-UTI due to E. coli (including 150 QREc) were analyzed. RESULTS: By univariate analysis QREc was associated to males, older patients, nursing home residents, functionally dependent, dementia, diabetes, cardiovascular diseases, immunosupression, nephrolithiasis, recurrent UTI, invasive procedures, hospitalization, and antibiotic use within previous 6 months. By multivariate analysis, use of ciprofloxacin (OR 20.6 [CI 2.3-179.2], p=0.006) or ofloxacin (OR 7.5 [CI 2.9-19.4], p<0.0001), previous invasive procedure (OR 6.6 [CI 3.0-14.7], p<0.0001), recurrent UTI (OR 4.7 [CI 2.3-9.3], p<0.0001), and previous hospitalization (OR 2.9 [CI 1.4-6], p=0.003) were identified as independent risk factors for COMA-UTI due to QREc. CONCLUSION: In patients with one or more of the risk factors identified here, the empiric use of quinolones should be reconsidered.
Authors: Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach Journal: Infect Control Hosp Epidemiol Date: 2013-08-23 Impact factor: 3.254
Authors: A Smithson; C Chico; J Ramos; C Netto; M Sanchez; J Ruiz; R Porron; M T Bastida Journal: Eur J Clin Microbiol Infect Dis Date: 2011-07-15 Impact factor: 3.267
Authors: B Kim; J Kim; M-R Seo; S-H Wie; Y K Cho; S-K Lim; J S Lee; K T Kwon; H Lee; H J Cheong; D W Park; S Y Ryu; M-H Chung; M Ki; H Pai Journal: Infection Date: 2013-03-16 Impact factor: 3.553
Authors: Christina F M van der Donk; Jeroen H B van de Bovenkamp; Els I G B De Brauwer; Patrick De Mol; Karl-Heinz Feldhoff; Wiltrud M Kalka-Moll; Sita Nys; Inge Thoelen; Thera A M Trienekens; Ellen E Stobberingh Journal: PLoS One Date: 2012-10-17 Impact factor: 3.240